Blood donations were first screened for Hepatitis B throughout the UK, however, the screening tests used then were imprecise. Read more about Blood donations were first screened for Hepatitis B throughout the UK, however, the screening tests used then were imprecise.
A World Health Organization Scientific Group reported: "The present widely employed techniques for detecting hepatitis B antigen in blood are thought to be capable of preventing approximately 30% of cases of post-transfusion hepatitis." Read more about A World Health Organization Scientific Group reported: "The present widely employed techniques for detecting hepatitis B antigen in blood are thought to be capable of preventing approximately 30% of cases of post-transfusion hepatitis."
Richard Gutowski wrote in a memo to Sammy Sinclair on Hepatitis C compensation that the Government's position was that they did not believe financial assistance was justified. Read more about Richard Gutowski wrote in a memo to Sammy Sinclair on Hepatitis C compensation that the Government's position was that they did not believe financial assistance was justified.
Sammy Sinclair requested a note for Dr Reid regarding financial assistance for people infected with Hepatitis C through blood or blood products that set out the background and issues plus the latest state of play and the suggested line to take. Read more about Sammy Sinclair requested a note for Dr Reid regarding financial assistance for people infected with Hepatitis C through blood or blood products that set out the background and issues plus the latest state of play and the suggested line to take.
A Westminster Hall debate addressed the subject of people infected with Hepatitis C through blood products. Read more about A Westminster Hall debate addressed the subject of people infected with Hepatitis C through blood products.
The report which Susan Deacon had requested on whether people with haemophilia in Scotland had been exposed to unnecessary risk of Hepatitis C through infected blood products in the mid 1980s sought to steer her "very firmly in the direction of not agreeing to compensation or special priority treatment for Hep C sufferers who may have been infected by NHS treatment". Read more about The report which Susan Deacon had requested on whether people with haemophilia in Scotland had been exposed to unnecessary risk of Hepatitis C through infected blood products in the mid 1980s sought to steer her "very firmly in the direction of not agreeing to compensation or special priority treatment for Hep C sufferers who may have been infected by NHS treatment".
The parameters of the Skipton Fund as then proposed were confirmed in a full submission to the Secretary of State on 6 January 2004 and announced on 23 January 2004. Read more about The parameters of the Skipton Fund as then proposed were confirmed in a full submission to the Secretary of State on 6 January 2004 and announced on 23 January 2004.
The Skipton Fund Appeals Panel was chaired by Mark Mildred who was an experienced solicitor who had previously been involved in the litigation brought by people with haemophilia who had contracted HIV, and had informally advised the claimants' legal teams in litigation concerning Hepatitis C and variant Creutzfeldt-Jakob disease. Read more about The Skipton Fund Appeals Panel was chaired by Mark Mildred who was an experienced solicitor who had previously been involved in the litigation brought by people with haemophilia who had contracted HIV, and had informally advised the claimants' legal teams in litigation concerning Hepatitis C and variant Creutzfeldt-Jakob disease.
The Skipton Fund Appeals Panel consisted of five members: a legal professional, three medical members (GP, haematologist and hepatologist) and a lay member. Read more about The Skipton Fund Appeals Panel consisted of five members: a legal professional, three medical members (GP, haematologist and hepatologist) and a lay member.
In his written evidence, Mark Mildred (chair of the Skipton Fund Appeals Panel) noted in relation to intravenous drug use: "More extensive disclosure and oral evidence tested by cross-examination might have given a more detailed picture and a better informed basis for the assessment of credibility but these were not open to us." Read more about In his written evidence, Mark Mildred (chair of the Skipton Fund Appeals Panel) noted in relation to intravenous drug use: "More extensive disclosure and oral evidence tested by cross-examination might have given a more detailed picture and a better informed basis for the assessment of credibility but these were not open to us."